Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29797543 | 1.00 | GPR119 (0.47) | GPR119NAMPTCA1CA2AKT1 | |
| SCHEMBL2048612 | 0.88 | GPR119 (0.46) | GPR119NAMPT | |
| SCHEMBL23270115 | 0.81 | CLK4 (0.46) | GPR119MAPT | |
| SCHEMBL25495766 | 0.81 | NAMPT (0.48) | GPR119NAMPTCA1CA2NQO2 | |
| SCHEMBL25444801 | 0.80 | IDO1 (0.48) | CA1IDO1MAPT | |
| SCHEMBL29902218 | 0.80 | IDO1 (0.48) | CA1IDO1MAPT | |
| SCHEMBL5846227 | 0.77 | GPR119 (0.53) | GPR119CA1MAPT | |
| SCHEMBL30627616 | 0.77 | NAMPT (0.51) | NAMPTCA1CA2AKT1NQO2 | |
| SCHEMBL30627612 | 0.77 | NAMPT (0.51) | NAMPTCA1CA2NQO2IDO1 | |
| SCHEMBL12110537 | 0.76 | NAMPT (0.46) | NAMPTCA1CA2AKT1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-11 | — | — | US | disclosed |
| WO-2021127460-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | GPR119 42/4885NAMPT 2275/4885CA1 4496/4885 |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | GPR119 87/4885NAMPT 1272/4885CA1 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.